Shear sensitivity is the silent challenge behind many advanced biomanufacturing modalities. Orbital-shaken bioreactors—often underestimated—may be a key enabler your CMC development is missing.

Tibor Anderlei, CSO at Kühner Shaker, joined David Brühlmann on the Smart Biotech Scientist Podcast to unpack the hidden physics behind bioprocess reproducibility and next-generation shaking technology. He has seen firsthand how overlooking fundamental parameters can derail scale-up and delay development timelines. In his role, Tibor is responsible for the customer interface—spanning sales, service, support, GMP topics, troubleshooting, marketing, and applied technology—with a focus on orbital shaking technology and small-scale cultivation support.

Topics discussed:

• The importance of measuring oxygen transfer rate (OTR) and carbon dioxide transfer rate (CTR) for reproducible bioprocesses—why DO is not sufficient (02:55)
• Real-time process analytical technology (PAT) for small-scale bioreactors, including microtiter plates and shake flasks (06:47)
• Pre-culture reproducibility: transferring at the right OTR and its impact on main cultures (07:56)
• Price sensitivity and scale-up challenges in cultivated meat—implications for media and equipment selection (10:36)
• Expansion of shaking technology to fields such as mixing, storage, and thawing, including applications in liquid crystal production (12:10)
• Leadership lessons from competing with bigger players: how smaller companies stay innovative, agile, and close to their customers (14:20)
• The significance of strong business partner relationships and trusting gut feeling in decision-making (16:32)
• Key advice for smart biotech scientists: careful definition of screening conditions and the use of online measurement tools at small scale (18:09)
• Accessible resources for mastering shaken bioreactor techniques, including webinars and direct contact with Tibor Anderlei (19:38)

Smart insight:

Treat small-scale shaken systems as real bioreactors and define screening conditions carefully from the start. Using online measurement tools even at early stages provides critical visibility and helps ensure that results are reproducible and scalable.

Building a robust scale-up strategy requires looking at the process from multiple angles—regulatory, digital, and operational. Listen to those previous episodes:

• Episode 03 - 04: How to Master Biotech Scale-up Without Guesswork with Leonardo Sibilio
• Episode 25 - 26: 9 Critical Steps for a Seamless Transition to Large-Scale Production
• Episode 231-232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann
• Episode 233-234: Why Most Bioprocess Automation Projects Fail with Anthony Catacchio
• Episode 237-238: High-Throughput Microbial Screening with Sebastian Blum

Connect with Tibor Anderlei:

LinkedIn: www.linkedin.com/in/tibor-anderlei-66342411/

Kühner Shaker website: www.kuhner.com

Shaking Technology Forum: www.shakingtechnology.com

Support the show

Why do small-scale bioprocess experiments often fail to translate in scale-up despite “perfect” results on paper?

Tibor Anderlei, Chief Scientific Officer and leader of customer support at Kühner Shaker, has spent three decades solving an issue that frustrates CMC leaders and biomanufacturing teams worldwide. He pioneered online monitoring in shake flasks, co-founded AC Biotec, and now helps organizations avoid costly trial-and-error with high-throughput screening and orbital shaken bioreactors.

Topics discussed:

• Why orbital shaken bioreactors are fundamental to successful bioprocess development (03:11)
• The gap between educational practices and real-world bioreactor expertise (04:00)
• Tibor Anderlei’s journey from the Technical University of Aachen to pioneering online monitoring technology in shake flasks (04:27)
• Reasons why published shake flask and microtiter plate experiments often fail to be reproduced in other labs (09:47)
• Key parameters frequently omitted from publications—including shaking diameter—and their impact on experiment reproducibility (13:10)
• Practical considerations for using microtiter plates and tubes, including automation compatibility and critical shaking speeds (14:13)
• Common scale-up failures due to oxygen limitation and mismatched aeration rates between small-scale and bioreactor systems (22:22)
• The effect of bioreactor geometry, such as neck shape, on process ventilation and performance (24:49)

Smart insight: If scientists want scalable, reproducible success, the path starts with getting the details right—and keeping a sharp eye on both automation trends and the fundamentals of shaken cultures.

Listen to the full episode with Tibor Anderlei to unpack the real “missing links” in bioprocess reproducibility and how to bridge small-scale insight to CMC scale-up.

Building a robust scale-up strategy requires looking at the process from multiple angles—regulatory, digital, and operational. Listen to those previous episodes:

• Episode 03 - 04: How to Master Biotech Scale-up Without Guesswork with Leonardo Sibilio
• Episode 25-26: 9 Critical Steps for a Seamless Transition to Large-Scale Production
• Episode 231-232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann
• Episode 233-234: Why Most Bioprocess Automation Projects Fail with Anthony Catacchio
• Episode 237-238: High-Throughput Microbial Screening with Sebastian Blum

Connect with Tibor Anderlei:

LinkedIn: www.linkedin.com/in/tibor-anderlei-66342411/

Kühner Shaker website: www.kuhner.com

Shaking Technology Forum: www.shakingtechnology.com

One bad CDMO decision can cost you two years and your Series A. If you're navigating tech transfer, CDMO selection, or IND prep, let's talk before it gets expensive. Two slots open this month.

Support the show

When a single mismanaged tech transfer threatens an entire development program, pressure on CMC leaders and bioprocess teams is intense. The truth? Tech transfers aren’t a black box. They’re complex, but solvable with the right mindset and playbook.

In this episode, David Brühlmann explores the practical side of tech transfer and scale-up within the biotech industry. With more than 15 years of experience, he shares personal stories and industry-tested frameworks that help demystify the complexities of transferring technologies between sites or organizations. Instead of focusing solely on technical details, he emphasizes the crucial human and organizational factors that often decide project success or failure.

Key topics discussed:

• How mapping and managing stakeholders can resolve hidden issues and accelerate projects (01:55)
• Case studies highlighting the importance of environmental factors — like light exposure — in process performance and troubleshooting (05:50)
• A mass transfer checklist for bioprocess scale-up, with specific focus on equipment-related parameters (07:09)
• The build vs. outsource dilemma: how to choose what to keep in-house and what to partner out, depending on company strategy and project phase (08:05)
• A 12-week tech transfer preparation protocol, covering foundations, risk mitigation, and execution readiness (10:16)
• Lessons on leadership, prioritization, and effective delegation to avoid personal and organizational bottlenecks (13:28)

Whether you're overseeing a complex CMC program, navigating CDMO relationships, or planning your next scale-up, this episode offers concrete steps to cut through confusion and deliver results.

If you’re interested in the ideas discussed, here are some of the guests David referenced in this episode.

• Episodes 91 - 92: Mass Transfer Secrets: Mastering Bubbles and kLa from Bench to Large-Scale Production with Lars Puiman & Rik Volger
• Episodes 79 - 80: Think Before You Build: Holistic Approaches to Biotech Facility Design with Alfredo Martínez Mogarra
• Episodes 57 - 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls with Matthias Müllner
• Episodes 23 - 24: Strategies for Success: Master CMC Development with Gene Lee

Support the show

What if the hidden cost of your bioprocess lies not in the technology, but in what you don’t document?

Too often, biotech teams discover too late that their “proven” process is just an illusion, propped up by undocumented tricks and missing critical parameters. In this episode, David Brühlmann strips down the assumptions behind scale-up and tech transfer, exposing the silent risks that threaten CMC milestones and market launches alike. After 15 years guiding biotech projects from bench to clinic, he’s felt the pain of process gaps, regulatory curveballs, and million-dollar mistakes. Here, he turns that experience into a tactical guide designed to save you from the same pitfalls.

In this episode, you’ll learn about:

• The 6-pillar approach to turning tech transfer into a managed process, rather than a gamble (03:09)
• Why mass transfer physics and factors like kLA are critical—and how they can make or break a process at scale (05:12)
• The importance of analytical comparability, including the common blind spots in sampling plans and method validation (07:19)
• Establishing a solid Quality by Design (QbD) foundation and defining critical quality attributes before transfer, not after failures (08:33)
• Stakeholder management and why non-technical challenges often derail projects (with more on this in Part 2) (10:09)
• Evaluating CDMO partners: What selection criteria really matter for long-term success and risk mitigation (11:03)
• Strategic decision-making: Building core capabilities versus outsourcing, and how to avoid unnecessary costs and delays (12:22)

This episode sets the stage for Part 2, where David Brühlmann will share practical stories and detailed frameworks for real-world implementation. If you manage bioprocess scale-up, tech transfer, or CMC development, you’ll find plenty of actionable insights to apply in your own work.

If you’re interested in the ideas discussed, here are some of the guests David referenced in this episode.

• Episodes 91 - 92: Mass Transfer Secrets: Mastering Bubbles and kLa from Bench to Large-Scale Production with Lars Puiman & Rik Volger
• Episodes 79 - 80: Think Before You Build: Holistic Approaches to Biotech Facility Design with Alfredo Martínez Mogarra
• Episodes 57 - 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls with Matthias Müllner
• Episodes 23 - 24: Strategies for Success: Master CMC Development with Gene Lee

Support the show

What if the solution to cell therapy’s biggest cold-chain challenge comes from the biology of Arctic fish?

This conversation features Steve Oh, a leader in advanced bioprocessing, whose career has placed him at the intersection of stem cell biology, process engineering, and clinical translation. Steve Oh joins David Brühlmann to share how XT Thrive®—a next-generation cryopreservation solution drawing from nature’s antifreeze proteins—lets cells survive, thrive, and simplify manufacturing from the bench to the clinic.

Episode highlights:

• Biological insights from Arctic fish and their translation into synthetic peptide chemistry for cell preservation (00:23)
• The effect of ice crystal formation on cellular damage, and how XT Thrive® minimizes this compared to DMSO (05:32)
• Simplified logistics: reduced risk of contamination, elimination of post-thaw wash steps, and implications for therapy delivery to remote locations (07:23)
• Applicability beyond single cells—preserving organoids and potential implications for tissue engineering (09:50)
• The ease of transitioning from DMSO to the new solution in established lab protocols (10:49)
• Broader industry challenges: maintaining purity, process optimization, and reducing cost of goods in cell therapy manufacturing (12:03)
• Promising innovations in rapid cell type differentiation and barriers to scaling transformative biotech (12:50)
• The importance of supporting innovative therapies beyond short-term ROI (14:17)

Smart insight:

Next-generation cryopreservation solutions address more than just viability—they simplify transport, reduce costs, lower hands-on time, and help ensure therapy reaches patients in remote locations in optimal condition. As Steve Oh observes, these advances are critical for reducing the cost of goods, improving consistency, and enabling truly scalable cell therapy manufacturing.

If you’re interested in this topic, check out these episodes, where we explore how Minnesota’s frozen forests inspired a new wave of biotech innovation—transforming how life-saving cells are frozen, stored, and shipped.

• Episodes 161 - 162: How to Achieve 85%+ Cell Recovery Without DMSO's Toxic Side Effects with Jeffrey Allen

This is Steve’s second appearance on the podcast. You can also catch his earlier conversation with David, where they explored the challenges and opportunities of cell and gene therapy.

• Episodes 11 - 12: From Lab to Patient: Steve Oh’s Guide to Mastering Cell Therapy Process Development.

Connect with Steve Oh:

Email: skwohso@gmail.com

LinkedIn: www.linkedin.com/in/steve-oh-4946261/

Support the show

Arctic fish survive in waters that would freeze most life solid. Not because they tolerate ice, but because their biology prevents crystals from forming in the first place. That same principle, translated into synthetic peptide chemistry, is now showing performance data that DMSO cannot match. Part 2 is where the science becomes practical.

Steve Oh spent 22 years at Singapore's A*STAR accumulating 43 patents across stem cell bioprocessing, microcarrier technologies, and serum-free media. He now advises XTherma, where he has been stress-testing their DMSO-free cryopreservation solution across T cells, MSCs, organoids, and beyond. In Part 2, he brings the data.

Key topics discussed:

• How antifreeze protein-inspired peptide chemistry reduces ice crystal size and protects cells during freezing and thawing (00:23)
• T cell and MSC performance data comparing XT Thrive to DMSO and CryoStor CS10, including a 2.5-fold increase in cell yield on microcarriers post-thaw (02:23-05:00)
• Why ice crystal formation causes more damage during thawing than freezing, and how XT Thrive addresses this (05:32)
• Elimination of the post-thaw wash step and what that means for contamination risk and manufacturing simplicity (07:00)
• Hold time extended to 24 hours and storage performance across 4°C, -80°C, and -196°C (08:01)
• Applicability beyond single cells: organoids, islets, and potential implications for organ preservation (09:50)
• How to transition from DMSO to XT Thrive: GMP grade, Drug Master File, same concentration, no protocol overhaul required (10:49)
• Broader cell therapy challenges: differentiation time, cell population consistency, and cost of goods (12:03)

Smart insight:

The transition away from DMSO is more accessible than most scientists assume. XT Thrive is GMP-grade, carries a Drug Master File, and is used at the same 5-10% concentration as DMSO, making it a plug-and-play substitution for most cell types. The manufacturing implications go further: no wash step, extended hold times, and storage stability across all standard temperature ranges simplify both production workflows and cold-chain logistics to remote treatment sites.

If you’re interested in this topic, check out these episodes, where we explore how Minnesota’s frozen forests inspired a new wave of biotech innovation, transforming how life-saving cells are frozen, stored, and shipped.

• Episodes 161 - 162: How to Achieve 85%+ Cell Recovery Without DMSO's Toxic Side Effects with Jeffrey Allen

This is Steve’s second appearance on the podcast. You can also catch his earlier conversation with David, where they explored the challenges and opportunities of cell and gene therapy.

• Episodes 11 - 12: From Lab to Patient: Steve Oh’s Guide to Mastering Cell Therapy Process Development.

Connect with Steve Oh:

Email: skwohso@gmail.com

LinkedIn: www.linkedin.com/in/steve-oh-4946261/

Support the show

Why do CDMOs keep building bigger stainless-steel facilities while their margins erode and Asian competitors undercut them on price? And what happens when big pharma decides to stop outsourcing altogether? The business model that sustained the industry for two decades is under pressure from every direction, and for many CDMOs, standing still is no longer a neutral position.

In Part 2, Juergen Mairhofer, CEO of enGenes Biotech, shifts from the science to the stakes. Having spent over a decade building a company on licensing proprietary microbial technology rather than selling fermentation capacity, he brings a distinctive vantage point on where the CDMO industry is headed and what it will take to stay relevant.

Here are some of the topics discussed:

• The need for innovation to stay competitive against lower-cost regions, and why capacity-focused business models are running out of road (03:08)
• How continuous manufacturing creates a competitive edge for CDMOs operating in high-cost regions (05:49)
• Practical advice for piloting continuous processing, building partnerships, and taking calculated risks before competitors do (06:36)
• The parallel universe of batch and continuous manufacturing, and how this duality will shape the industry over the next decade (08:24)
• What scientists need to know before spinning out a technology company: customer focus, cash discipline, and why the team is everything (09:49)
• Big pharma's return to in-house manufacturing and vertical supply chain integration, and why this creates opportunity for innovation-focused partners (12:12)

Smart insight: Technology excellence is necessary but not sufficient. Juergen's closing word was simply "don't be afraid" and it carried weight precisely because it was not a platitude. The companies that will matter in ten years are those that start the hard work of innovation now, before the window closes.

If you’re interested in exploring more breakthroughs in continuous bioprocessing and the future of biotech manufacturing, check out these past episodes from the Smart Biotech Scientist Podcast:

• Episodes 85 - 86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo Morbidelli
• Episodes 153 - 154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago Matos
• Episode 155: From Process Bottlenecks to Seamless Production: How Continuous Bioprocessing Changes Everything
• Episode 156: The Hidden Economics of Continuous Processing That Most Biotech Companies Overlook
• Episodes 181 - 182: Innovating Continuous Bioprocessing with Vibrating Membrane Filtration with Jarno Robin
• Episodes 209 - 210: From Batch to Continuous: Building Innovation Culture in Conservative Biotech Environments with Irina Ramos

Connect with Juergen Mairhofer:

LinkedIn: www.linkedin.com/in/juergen-mairhofer-ab27a5b

enGenes Biotech GmbH website: www.engenes.cc

Support the show

What if continuous microbial manufacturing wasn't a pipe dream, but a reality quietly reshaping the foundations of bioprocessing?

Meet Juergen Mairhofer, CEO of enGenes Biotech GmbH and a scientist with a rare dual fluency in molecular biology and bioprocess engineering. He's not just optimizing at the margins. He's devised a proprietary E. coli platform that radically stabilizes genetic stability and splits cell growth from protein production. Instead of stretching out fermentation for a few more days, he's running continuous E. coli processes for up to 40 days; something most believed impossible.

Here's why this conversation is worth your notebook and a second listen:

• Why the commodity CDMO model struggles with innovation and how enGenes Biotech's model aligns business incentives with process improvement (02:37)
• Juergen Mairhofer's early experiences blending molecular biology and bioprocess engineering, and how a "DIY" mentality led to entrepreneurship (04:42)
• Strategy behind developing a proprietary E. coli strain that decouples protein production from cell growth (10:01)
• The benefits of continuous manufacturing: running up to 40-day E. coli processes, and how this compares to mammalian (CHO) systems (13:57)
• Economic and operational advantages: reducing facility footprint, lowering CAPEX/OPEX, and the necessity for innovation in global competition (19:25)
• How enGenes Biotech integrates upstream and downstream operations for fully end-to-end continuous production (17:50)
• Specific technical challenges: managing genetic drift, sterility, equipment, and process modeling in continuous systems (21:10)

Smart insight: Technology excellence is the entry ticket, but it won't sell itself. The companies that will lead the next decade of bioprocessing are those willing to align their business model with process innovation, not just capacity utilization.

If you’re interested in exploring more breakthroughs in continuous bioprocessing and the future of biotech manufacturing, check out these past episodes from the Smart Biotech Scientist Podcast:

• Episodes 85 - 86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo Morbidelli
• Episodes 153 - 154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago Matos
• Episode 155: From Process Bottlenecks to Seamless Production: How Continuous Bioprocessing Changes Everything
• Episode 156: The Hidden Economics of Continuous Processing That Most Biotech Companies Overlook
• Episodes 181 - 182: Innovating Continuous Bioprocessing with Vibrating Membrane Filtration with Jarno Robin
• Episodes 209 - 210: From Batch to Continuous: Building Innovation Culture in Conservative Biotech Environments with Irina Ramos

Connect with Juergen Mairhofer:

LinkedIn: www.linkedin.com/in/juergen-mairhofer-ab27a5b

enGenes Biotech GmbH website: www.engenes.cc

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

One bad CDMO decision can cost you two years and your Series A. If you're navigating tech transfer, CDMO selection, or IND prep, let's talk before it gets expensive. Two slots open this month.

Support the show